Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Saudi Arabia has shown significant growth over the past few years.
Customer preferences: Saudi Arabia is witnessing an increase in the prevalence of hypertension, which is driving the demand for anti-hypertensive drugs. The aging population, unhealthy lifestyles, and genetic factors are contributing to the rise in hypertension cases. As a result, patients are increasingly seeking effective and affordable treatment options.
Trends in the market: The Anti-Hypertensive Drugs market in Saudi Arabia is dominated by branded drugs, with a few generic drugs available. However, the market is expected to shift towards generic drugs due to the government's initiatives to reduce healthcare costs. The government has implemented policies to encourage the use of generic drugs by increasing their availability and reducing their prices. This shift towards generic drugs is expected to increase competition in the market and reduce the prices of anti-hypertensive drugs.
Local special circumstances: Saudi Arabia has a unique healthcare system, where the government provides free healthcare to all citizens. However, the government is facing challenges in managing the rising healthcare costs due to the increasing demand for healthcare services. To address this challenge, the government is implementing policies to reduce healthcare costs, which include promoting the use of generic drugs. Additionally, the government is investing in healthcare infrastructure and technology to improve the quality of healthcare services.
Underlying macroeconomic factors: Saudi Arabia is the largest economy in the Middle East and North Africa region and is heavily dependent on oil exports. The recent decline in oil prices has had a significant impact on the country's economy, leading to a decrease in government spending. However, the government is focusing on diversifying the economy and reducing its dependence on oil exports. This diversification is expected to create new opportunities for the healthcare sector, including the Anti-Hypertensive Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
